J. Haarbo et al., AORTIC PERMEABILITY TO LDL DURING ESTROGEN THERAPY - A STUDY IN NORMOCHOLESTEROLEMIC RABBITS, Arteriosclerosis and thrombosis, 14(2), 1994, pp. 243-247
17 beta-Estradiol has recently been found to inhibit atherogenesis by
mechanisms that are in part independent of the estrogenic action on pl
asma lipoprotein levels. Since aortic permeability to low-density lipo
protein (LDL) in normocholesterolemic rabbits is a strong predictor fo
r subsequent atherosclerosis during hypercholesterolemia, the present
study investigated a possible influence of 17 beta-estradiol on aortic
permeability to LDL. Twenty rabbits were initially ovariectomized and
then fed a nonatherogenic diet for 10 weeks. One group of rabbits (n=
10) received 4 mg of 17 beta-estradiol orally per day; the other group
(n=10) received placebo. Serum concentrations of very-low-density lip
oprotein cholesterol and triglycerides increased significantly more in
the placebo group than in the estrogen group (P<.03), whereas there w
ere no statistically significant differences between groups in LDL, hi
gh-density lipoprotein, or total cholesterol. At the end of the experi
ment, I-125-LDL was injected intravenously into each rabbit. Aortas we
re removed 3 hours later, and the aortic permeability to LDL was calcu
lated from the radioactivity in the plasma and the aortic intima/inner
media. The aortic permeability to LDL was virtually identical in the
17 beta-estradiol (31.6+/-7.2 nL.cm(-2).h(-1)) and the placebo (36.9+/
-7.9 nL.cm(-2).h(-1)) groups (mean+/-SEM). The aortic cholesterol cont
ent was also similar in the two groups. These data suggest that the pl
asma lipid-independent antiatherogenic effect of estradiol is not medi
ated through an effect on aortic permeability to LDL but rather is rel
ated to the metabolism of the lipoproteins after they have entered the
arterial wall.